Loading, please wait ...

News Analytics

Kymera Therapeutics HeteroBifunctional Molecule Protein Degredation process no arrows jpg?VersionId=cl0UAJ124w28G1YG W7 OAqHdz ClGzH.
Kymera Therapeutics raised $65 million in series B funding that will support the clinical development of its lead protein degradation program, as well as advance its other preclinical assets. CEO Laurent Audoly kept mum on specific targets and indications, saying that “at this point, what we are comfortable saying is we’re focused on oncology.” The Cambridge, Massachusetts-based biotech is one ...

The Angle

Subject Matter

  • Science and technology 65.38%
  • Business, economics, society 34.62%
    • Companies, industries, organizations 100.00%

Emotional Reaction






Dimensions/Depth Chart

If you find a dimension intereseting, we recommend you pick up one or two facts that you find intriguing and place them into your memory. That way you will have 2nd degree information about the topic if it comes up in conversation.

Accordingly, you can do the same with others as well.